Item 7.01 Regulation FD Disclosure.

On January 11, 2021, the Company issued a press release announcing it was granted two fast track designations from the U.S. Food and Drug Administration for Cavrotolimod (AST-008).

A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 to this Current Report on Form 8-K, and including Exhibit 99.1 furnished herewith, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


--------------------------------------------------------------------------------



Item 9.01  Financial Statements and Exhibits.
  Exhibit
    No.                        Description
99.1             Press release dated January 11, 2021.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses